10-Q: TNF Pharmaceuticals Reports Q3 2024 Results, Cites Ongoing Development of MYMD-1 and Supera-CBD

TNF Pharmaceuticals reported its Q3 2024 financial results, highlighting ongoing development of its MYMD-1 and Supera-CBD therapeutic platforms and recent financing activities.

Summary

• TNF Pharmaceuticals reported a net loss of $21.295 million for the nine months ended September 30, 2024.
• The company's cash and marketable securities totaled $10.64 million as of September 30, 2024.
• Operating expenses for the nine months totaled $7.98 million, with research and development expenses at $2.31 million.
• The company has been focused on developing MYMD-1 for age-related illnesses and Supera-CBD for various conditions including epilepsy and pain.
• Recent financing activities include the issuance of Series F-1 and Series G Preferred Stock, raising $12.487 million net of offering costs.
• The company has also been managing its debt and equity structure, including amendments to preferred stock agreements and warrant modifications.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has made progress in its research and development programs and secured additional funding, the significant net loss and ongoing financial challenges temper the overall sentiment. The company's future success is highly dependent on the successful development and commercialization of its product candidates.

Positives

• The company successfully raised $12.487 million through the issuance of Series F-1 and Series G Preferred Stock.
• The company completed a 90-day oral gavage EEG safety study for MYMD-1, a key step in its development.
• The company is actively progressing the development of both MYMD-1 and Supera-CBD therapeutic platforms.
• The company has been managing its debt and equity structure, including amendments to preferred stock agreements and warrant modifications.

Negatives

• The company reported a significant net loss of $21.295 million for the nine months ended September 30, 2024.
• The company's operating expenses remain high, with research and development costs at $2.31 million for the nine months.
• The company has a significant accumulated deficit of $126.002 million.
• The company has recognized a loss on the issuance of preferred stock of approximately $5.1 million.
• The company has recognized a loss of $7,094,000 related to the change in fair value of the Series F Warrant liabilities through the March 31, 2024 reclassification of Series F Warrant liabilities to equity.

Risks

• The company's ability to achieve profitability is dependent on the successful development and commercialization of its product candidates.
• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• The company is subject to risks associated with clinical trials, regulatory approvals, and market acceptance of its products.
• The company's financial results are subject to fluctuations due to changes in fair value of derivatives and warrants.
• The company is subject to risks associated with the terms of its preferred stock and warrant agreements, including anti-dilution provisions and redemption obligations.
• The company is subject to risks associated with the terms of its preferred stock and warrant agreements, including anti-dilution provisions and redemption obligations.
• The company is subject to risks associated with the terms of its preferred stock and warrant agreements, including anti-dilution provisions and redemption obligations.

Future Outlook

The company believes its current financial resources are sufficient to fund its operating budget and contractual obligations for the next twelve months. The company is focused on advancing the development of MYMD-1 and Supera-CBD and exploring non-dilutive opportunities for MYMD-1.

Management Comments

• The company is focused on developing and commercializing two therapeutic platforms based on well-defined therapeutic targets: MYMD-1 and Supera-CBD.
• The company is advancing MYMD-1 in sarcopenia based on positive clinical data from its Phase II trial and previous research findings.
• The company is currently preparing several scientific papers for publication in 2024, including an abstract for submission in the fourth quarter 2024 related to the Phase 2 study of MYMD-1 in sarcopenia/frailty to a peer-reviewed publication.
• The company is exploring non-dilutive opportunities to evaluate MYMD-1 in additional indications not previously considered.

Industry Context

The company operates in the competitive pharmaceutical and biotechnology industry, focusing on developing novel therapies for age-related illnesses and other conditions. The company's focus on TNF-alpha and IL-6 inhibition with MYMD-1 and the CB2 receptor with Supera-CBD aligns with current trends in drug development.

Comparison to Industry Standards

• The company's financial performance, with a significant net loss and high operating expenses, is not uncommon for early-stage biotechnology companies focused on research and development.
• The company's cash position of $10.64 million is relatively low compared to some of its peers, highlighting the need for continued financing.
• The company's focus on novel therapeutic targets and platforms is consistent with industry trends, but the success of these programs is not guaranteed.
• The company's reliance on private placements for funding is a common strategy for early-stage biotech companies, but it can lead to dilution for existing shareholders.
• The company's management of its debt and equity structure, including amendments to preferred stock agreements and warrant modifications, is a common practice in the industry to manage financial obligations and capital structure.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in ongoing litigation with Raymond Akers, with the Second Raymond Akers Action currently in the discovery phase.

Related Party Transactions

• The company has royalty agreements with SRQ Patent Holdings and SRQ Patent Holdings II, affiliates of Mr. Jonnie Williams, Sr.
• The company has a license agreement with MIRA Pharmaceuticals, Inc.
• The company issued Series G Preferred Stock to investors, including PharmaCyte Biotech, Inc., where Joshua Silverman, the company's Chairman of the Board, serves as the interim CEO, President and Director.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares for financing and debt settlement.
• Employees may be affected by cost-cutting measures and changes in management.
• Customers and patients may benefit from the development of new therapies, but the timeline for commercialization is uncertain.
• Creditors may be impacted by the company's financial performance and ability to meet its obligations.
• Suppliers may be affected by changes in the company's operations and financial condition.

Next Steps

• The company will continue to advance the development of MYMD-1 and Supera-CBD.
• The company will prepare several scientific papers for publication in 2024.
• The company will explore non-dilutive opportunities to evaluate MYMD-1 in additional indications.
• The company will continue to manage its debt and equity structure.

Key Dates

Keywords

MYMD-1, Supera-CBD, Pharmaceuticals, Biotechnology, Clinical Trials, Preferred Stock, Warrants, Sarcopenia, Immunometabolic, Inflammation, Neurodegenerative, Drug Development